CoChat
Cited by 169

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

Open access
Raghu, Ganesh, Montesi, Sydney B., Silver, Richard M., Hossain, Tanzib, Macrea, Madalina, Herman, Derrick, Barnes, Hayley, Adegunsoye, Ayodeji, Azuma, Arata, Chung, Lorinda, Gardner, Gregory C., Highland, Kristin B., Hudson, Marie, Kaner, Robert J., Kolb, Martin, Scholand, Mary Beth, Steen, Virginia, Thomson, Carey C., Volkmann, Elizabeth R., Wigley, Fredrick M., Burlile, Dee, Kemper, Karen A., Knight, Shandra L., Ghazipura, Marya · 2024 · American Journal of Respiratory and Critical Care Medicine

Abstract

Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding treatment for patients with SSc-ILD are primarily consensus based. Methods: An international expert guideline committee composed of 24 individuals with expertise in rheumatology, SSc, pulmonology, ILD, or methodology, and with personal experience with SSc-ILD, discussed systematic reviews of the published evidence assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Predetermined conflict-of-interest management strategies were applied, and recommendations were made for or against specific treatment interventions exclusively by the nonconflicted panelists. The confidence in effect estimates, importance of outcomes studied, balance of desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications for health equity were all considered in making the recommendations. This was in accordance with the American Thoracic Society guideline development process, which is in compliance with the Institute of Medicine standards for trustworthy guidelines. Results: For treatment of patients with SSc-ILD, the committee: 1) recommends the use of mycophenolate; 2) recommends further research into the safety and efficacy of (a) pirfenidone and (b) the combination of pirfenidone plus mycophenolate; and 3) suggests the use of (a) cyclophosphamide, (b) rituximab, (c) tocilizumab, (d) nintedanib, and (e) the combination of nintedanib plus mycophenolate. Conclusions: The recommendations herein provide an evidence-based clinical practice guideline for the treatment of patients with SSc-ILD and are intended to serve as the basis for informed and shared decision making by clinicians and patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202306-1113st

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Raghu, G., Montesi, S. B., Silver, R. M., Hossain, T., Macrea, M., Herman, D., Barnes, H., Adegunsoye, A., Azuma, A., Chung, L., Gardner, G. C., Highland, K. B., Hudson, M., Kaner, R. J., Kolb, M., Scholand, M. B., Steen, V., Thomson, C. C., Volkmann, E. R., Wigley, F. M., Burlile, D., Kemper, K. A., Knight, S. L., & Ghazipura, M.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2024-01
Volume
209
Issue
2
Pages
137-152
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4387157834
Cited by
169
References
6
FWCI
27.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. https://app.cochat.ai/papers/10.1164/rccm.202306-1113st
The paper
Raghu, G., Montesi, S. B., Silver, R. M., Hossain, T., Macrea, M., Herman, D., Barnes, H., Adegunsoye, A., Azuma, A., Chung, L., Gardner, G. C., Highland, K. B., Hudson, M., Kaner, R. J., Kolb, M., Scholand, M. B., Steen, V., Thomson, C. C., Volkmann, E. R., . . . Ghazipura, M. (2024). Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202306-1113st

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.